Dare Bioscience Inc (DARE)

$0.74 +0.03 (4.29%)
Market Cap 13.89M
Revenue (ttm) 1.03M
Net Income (ttm) -13.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,300.97%
Debt to Equity Ratio 0.00
Volume 425,158
Avg Vol 589,528
Day's Range N/A - N/A
Shares Out 19.67M
Stochastic %K 12%
Beta 1.01
Analysts Strong Sell
Price Target $8.33

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
supersox
supersox Sep. 14 at 4:34 PM
$DARE way too cheap
1 · Reply
StackingWins999
StackingWins999 Sep. 14 at 4:33 PM
$DARE volume picking up today… let’s go
0 · Reply
darebio
darebio Sep. 14 at 2:30 PM
$DARE Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-peer-reviewed-publication-phase-1
0 · Reply
focafoca99
focafoca99 Sep. 14 at 1:00 PM
$DARE detailed its Phase 1 sildenafil cream study showing 187-fold lower exposure vs oral. https://www.rapidticker.com/news/dare-daré-bioscience-announces-peer-reviewed-56f8a8
0 · Reply
DM3D
DM3D Sep. 11 at 8:53 PM
$DARE I'm so sorry to my fellow investors. We DAREd to trust. I feel the company failed us in so many ways. Investing is risky and this company epitomizes why.
1 · Reply
darebio
darebio Sep. 11 at 5:20 PM
$DARE Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand. View the video webcast here: https://journey.ct.events/view/731ba830-7bd5-46f7-8fbd-f6545b5ec5ac Full Press Release: https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-presentation-hc-wainwright-28th-annual-global
0 · Reply
focafoca99
focafoca99 Sep. 11 at 11:05 AM
$DARE made its H.C. Wainwright conference presentation available on-demand. https://www.rapidticker.com/news/dare-daré-bioscience-presentation-for-hc-892da2
0 · Reply
setforyou
setforyou Sep. 10 at 10:18 AM
$AIM I asked Grok the hot penny stocks to buy and swing! $ELBM $WKSP $WKSP $DARE $LUCY
0 · Reply
Delthefunkeehomosapian
Delthefunkeehomosapian Sep. 9 at 9:25 PM
$DARE 5000 share wall on .70 and the ask at .79 in AH. It will probably punch beneath .70 again tomorrow. I' m just keep scalping away.
0 · Reply
StockJayC
StockJayC Sep. 9 at 3:29 PM
$DARE How is Sabrina still ceo of this company... Got 1 investment of Mackenzie Bezos and thinks she can build a Bn$ healthcare company
0 · Reply
Latest News on DARE
Dare Bioscience publishes results from Sildenafil Cream study

2026-09-14T13:05:23.000Z - 8 hours ago

Dare Bioscience publishes results from Sildenafil Cream study

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Sep 14, 2026, 8:50 AM EDT - 8 hours ago

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Daré Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 11, 2026, 7:00 AM EDT - 3 days ago

Daré Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Sep 11, 2026, 6:55 AM EDT - 3 days ago

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2

2026-08-31T13:00:32.000Z - 14 days ago

Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Aug 31, 2026, 8:44 AM EDT - 14 days ago

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Aug 27, 2026, 9:01 AM EDT - 18 days ago

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Daré Bioscience Transcript: Investor update

Aug 26, 2026, 3:30 PM EDT - 19 days ago

Daré Bioscience Transcript: Investor update

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Aug 26, 2026, 8:45 AM EDT - 19 days ago

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Daré Bioscience Registration statement: Registration filing

Aug 26, 2026, 8:00 AM EDT - 19 days ago

Daré Bioscience Registration statement: Registration filing

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Aug 25, 2026, 8:55 AM EDT - 20 days ago

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Aug 18, 2026, 9:02 AM EDT - 27 days ago

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Dare Bioscience announces pricing of $6M registered direct offering

2026-08-16T12:52:02.000Z - 4 weeks ago

Dare Bioscience announces pricing of $6M registered direct offering

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aug 14, 2026, 12:45 PM EDT - 4 weeks ago

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Daré Bioscience Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Daré Bioscience Earnings Call Transcript: Q2 2026

Daré Bioscience Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Daré Bioscience Quarterly report: Q2 2026

Daré Bioscience Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Daré Bioscience Earnings release: Q2 2026

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

Aug 13, 2026, 4:01 PM EDT - 4 weeks ago

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026

Aug 6, 2026, 9:05 AM EDT - 5 weeks ago

Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Jul 28, 2026, 8:34 AM EDT - 6 weeks ago

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Daré Bioscience Slides: Corporate presentation

Jul 24, 2026, 7:00 AM EDT - 7 weeks ago

Daré Bioscience Slides: Corporate presentation

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Jul 20, 2026, 9:01 AM EDT - 1 month ago

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Daré Bioscience Transcript: Virtual Investor Closing Bell

Jul 14, 2026, 4:00 PM EDT - 2 months ago

Daré Bioscience Transcript: Virtual Investor Closing Bell

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Jul 9, 2026, 8:43 AM EDT - 2 months ago

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Jul 1, 2026, 8:55 AM EDT - 2 months ago

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Jun 25, 2026, 9:05 AM EDT - 2 months ago

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Jun 18, 2026, 9:20 AM EDT - 2 months ago

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Daré Bioscience Transcript: AGM 2026

Jun 11, 2026, 12:00 PM EDT - 3 months ago

Daré Bioscience Transcript: AGM 2026

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Proxy statement: Proxy filing

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

2026-05-26T12:19:36.000Z - 3 months ago

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

May 26, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare Bioscience initiates DARE-HPV clinical study

2026-05-18T12:14:40.000Z - 3 months ago

Dare Bioscience initiates DARE-HPV clinical study

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

May 18, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Daré Bioscience Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Earnings Call Transcript: Q1 2026

Daré Bioscience Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Quarterly report: Q1 2026

Daré Bioscience Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Daré Bioscience Earnings release: Q1 2026

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:01 PM EDT - 4 months ago

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

2026-05-12T19:41:03.000Z - 4 months ago

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

May 12, 2026, 8:00 AM EDT - 4 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Earnings Call Transcript: Q4 2025

Daré Bioscience Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Annual report: Q4 2025

Daré Bioscience Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Earnings release: Q4 2025

Daré Bioscience Slides: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Slides: Q4 2025

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Mar 23, 2026, 8:00 AM EDT - 5 months ago

On National Viagra Day, Women Finally Claim Their Turn:

Dare Bioscience receives NIH funding award notice for DARE-PTB1

2026-03-16T12:39:51.000Z - 6 months ago

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:40 PM EST - 6 months ago

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

2026-02-23T13:22:55.000Z - 6 months ago

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Feb 23, 2026, 8:00 AM EST - 6 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare announces availability of telehealth consultations for DARE to PLAY

2026-02-11T13:23:08.000Z - 7 months ago

Dare announces availability of telehealth consultations for DARE to PLAY

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

2025-12-10T13:10:49.000Z - 9 months ago

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 9 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dare Bioscience announces return of rights to Oveprene

2025-12-01T13:20:39.000Z - 9 months ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience receives $3.6M in additional grant funding

2025-11-24T13:30:31.000Z - 9 months ago

Dare Bioscience receives $3.6M in additional grant funding

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Daré Bioscience Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Daré Bioscience Quarterly report: Q3 2025

Daré Bioscience Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Daré Bioscience Earnings release: Q3 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 10 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dare Bioscience to host webinar on the DARE to PLAY

2025-11-11T13:10:31.000Z - 10 months ago

Dare Bioscience to host webinar on the DARE to PLAY

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Dare Bioscience to receive up to $300,000 to conduct landscape review

2025-11-03T13:20:56.000Z - 10 months ago

Dare Bioscience to receive up to $300,000 to conduct landscape review

Dare Bioscience receives $4M non-dilutive grant installment

2025-10-06T12:20:36.000Z - 11 months ago

Dare Bioscience receives $4M non-dilutive grant installment

Dare Bioscience to receive up to $499,000 to support preeclampsia research

2025-09-24T12:11:38.000Z - 11 months ago

Dare Bioscience to receive up to $499,000 to support preeclampsia research

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 11 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Dare Bioscience upgraded to Buy from Hold at Maxim

2025-09-04T11:45:08.000Z - 1 year ago

Dare Bioscience upgraded to Buy from Hold at Maxim

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Daré Bioscience Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q2 2025

Daré Bioscience Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q2 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 1 year ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 1 year ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Proxy statement: Proxy Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Slides: Corporate Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Daré Bioscience Slides: Corporate Presentation

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

Daré Bioscience Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q1 2025

Daré Bioscience Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q1 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Daré Bioscience Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q4 2024

Daré Bioscience Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Annual report: Q4 2024

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Registration statement: Registration Filing

Nov 15, 2024, 7:00 AM EST - 1 year ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Daré Bioscience Earnings release: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings release: Q3 2024

Daré Bioscience Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Quarterly report: Q3 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Daré Bioscience Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q2 2024

Daré Bioscience Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q2 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 2 years ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

Daré Bioscience Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q1 2024

Daré Bioscience Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q1 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

supersox
supersox Sep. 14 at 4:34 PM
$DARE way too cheap
1 · Reply
StackingWins999
StackingWins999 Sep. 14 at 4:33 PM
$DARE volume picking up today… let’s go
0 · Reply
darebio
darebio Sep. 14 at 2:30 PM
$DARE Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-peer-reviewed-publication-phase-1
0 · Reply
focafoca99
focafoca99 Sep. 14 at 1:00 PM
$DARE detailed its Phase 1 sildenafil cream study showing 187-fold lower exposure vs oral. https://www.rapidticker.com/news/dare-daré-bioscience-announces-peer-reviewed-56f8a8
0 · Reply
DM3D
DM3D Sep. 11 at 8:53 PM
$DARE I'm so sorry to my fellow investors. We DAREd to trust. I feel the company failed us in so many ways. Investing is risky and this company epitomizes why.
1 · Reply
darebio
darebio Sep. 11 at 5:20 PM
$DARE Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand. View the video webcast here: https://journey.ct.events/view/731ba830-7bd5-46f7-8fbd-f6545b5ec5ac Full Press Release: https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-presentation-hc-wainwright-28th-annual-global
0 · Reply
focafoca99
focafoca99 Sep. 11 at 11:05 AM
$DARE made its H.C. Wainwright conference presentation available on-demand. https://www.rapidticker.com/news/dare-daré-bioscience-presentation-for-hc-892da2
0 · Reply
setforyou
setforyou Sep. 10 at 10:18 AM
$AIM I asked Grok the hot penny stocks to buy and swing! $ELBM $WKSP $WKSP $DARE $LUCY
0 · Reply
Delthefunkeehomosapian
Delthefunkeehomosapian Sep. 9 at 9:25 PM
$DARE 5000 share wall on .70 and the ask at .79 in AH. It will probably punch beneath .70 again tomorrow. I' m just keep scalping away.
0 · Reply
StockJayC
StockJayC Sep. 9 at 3:29 PM
$DARE How is Sabrina still ceo of this company... Got 1 investment of Mackenzie Bezos and thinks she can build a Bn$ healthcare company
0 · Reply
RMAW
RMAW Sep. 4 at 12:40 AM
$DARE Getting closer to my .65/.60/.55/.50 ladder buy orders!!! 🤪🔫
1 · Reply
Delthefunkeehomosapian
Delthefunkeehomosapian Sep. 3 at 10:10 PM
$DARE Scooped some more at .71. Guess this is just gonna go lower without any news.
1 · Reply
Zackpedia
Zackpedia Sep. 1 at 11:07 PM
$DARE Down to .7, you could’ve sold…
0 · Reply
Mike_Rotsch
Mike_Rotsch Aug. 31 at 2:49 PM
$DARE Back in, at .75.
0 · Reply
darebio
darebio Aug. 31 at 2:49 PM
$DARE Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-new-nih-funding-award-approximately
0 · Reply
focafoca99
focafoca99 Aug. 31 at 2:39 PM
$DARE bagged a new NIH award of about $908K to advance its preterm birth program. https://www.rapidticker.com/news/dare-daré-bioscience-announces-new-nih-e1eb22
0 · Reply
flychicken1991
flychicken1991 Aug. 31 at 12:58 PM
$DARE Positive (82%): The award supports DARE's stock price by covering eligible DARE-PTB2 development costs with non-dilutive funding, reducing the near-term financing burden associated with that program. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/74d5d32b015b4e4f/dare-dar-bioscience-announces-new-nih-funding-award-for-approximately-90?utm_source=stocktwits&utm_medium=story_url
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 31 at 12:44 PM
$DARE Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
0 · Reply
darebio
darebio Aug. 27 at 5:50 PM
$DARE CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here: https://virtualinvestorco.com/dare Press Release: https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-ceo-sabrina-martucci-johnson-participates
0 · Reply
DM3D
DM3D Aug. 27 at 3:16 PM
$DARE perhaps Sabrina's "Why Now" presentation with Virtual Investor should be more appropriatly done with Virtual Donations and be titled "Why Ever". I'm just speaking from personal experience as an "investor" here. They pretty much wiped out my shares in the last RS and I suppose another could be in offing. Hard to lable that "investing".
1 · Reply
VirtualInvestor
VirtualInvestor Aug. 27 at 2:23 PM
$DARE Participates in the Virtual Investor "Why Now" On-Demand Conference DARE CEO Sabrina Martucci Johnson shares why innovation in women’s health could help address longstanding gaps in care and create new possibilities for patients. https://vimeo.com/1221551789/07e0078f3f?fl=ml&fe=ec
0 · Reply
HMIC
HMIC Aug. 27 at 1:58 PM
$DARE
0 · Reply